Literature DB >> 20431066

Restoration of high-density lipoprotein levels by cholesteryl ester transfer protein expression in scavenger receptor class B type I (SR-BI) knockout mice does not normalize pathologies associated with SR-BI deficiency.

Reeni B Hildebrand1, Bart Lammers, Illiana Meurs, Suzanne J A Korporaal, Willeke De Haan, Ying Zhao, J Kar Kruijt, Domenico Praticò, Alinda W M Schimmel, Adriaan G Holleboom, Menno Hoekstra, Jan Albert Kuivenhoven, Theo J C Van Berkel, Patrick C N Rensen, Miranda Van Eck.   

Abstract

OBJECTIVE: Disruption of scavenger receptor class B type I (SR-BI) in mice impairs high-density lipoprotein (HDL)-cholesterol (HDL-C) delivery to the liver and induces susceptibility to atherosclerosis. In this study, it was investigated whether introduction of cholesteryl ester transfer protein (CETP) can normalize HDL-C transport to the liver and reduce atherosclerosis in SR-BI knockout (KO) mice. METHODS AND
RESULTS: Expression of human CETP in SR-BI(KO) mice resulted in decreased plasma HDL-C levels, both on chow diet (1.8-fold, P<0.001) and on challenge with Western-type diet (1.6-fold, P<0.01). Furthermore, the presence of CETP partially normalized the abnormally large HDL particles observed in SR-BI(KO) mice. Unexpectedly, expression of CETP in SR-BI(KO) mice did not reduce atherosclerotic lesion development, probably because of consequences of SR-BI deficiency, including the persistence of higher VLDL-cholesterol (VLDL-C) levels, unchanged elevated free cholesterol/total cholesterol ratio, and the increased oxidative status of the animals. In addition, CETP expression did not normalize other characteristics of SR-BI deficiency, including female infertility, reticulocytosis, thrombocytopenia, and impaired platelet aggregation.
CONCLUSIONS: CETP restores HDL-C levels in SR-BI(KO) mice, but it does not change the susceptibility to atherosclerosis and other typical characteristics that are associated with SR-BI disruption. This may indicate that the pathophysiology of SR-BI deficiency is not a direct consequence of changes in the HDL pool.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20431066     DOI: 10.1161/ATVBAHA.110.205153

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  23 in total

1.  Excess cholesterol induces mouse egg activation and may cause female infertility.

Authors:  Ayce Yesilaltay; Gregoriy A Dokshin; Dolores Busso; Li Wang; Dalia Galiani; Tony Chavarria; Eliza Vasile; Linda Quilaqueo; Juan Andrés Orellana; Dalia Walzer; Ruth Shalgi; Nava Dekel; David F Albertini; Attilio Rigotti; David C Page; Monty Krieger
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-03       Impact factor: 11.205

Review 2.  HDL and atherosclerotic cardiovascular disease: genetic insights into complex biology.

Authors:  Robert S Rosenson; H Bryan Brewer; Philip J Barter; Johan L M Björkegren; M John Chapman; Daniel Gaudet; Daniel Seung Kim; Eric Niesor; Kerry-Anne Rye; Frank M Sacks; Jean-Claude Tardif; Robert A Hegele
Journal:  Nat Rev Cardiol       Date:  2017-08-10       Impact factor: 32.419

3.  Coronary artery disease: Scavenger receptor class B1--a target to reduce CHD risk?

Authors:  Philip J Barter; Kerry-Anne Rye
Journal:  Nat Rev Cardiol       Date:  2016-04-07       Impact factor: 32.419

Review 4.  New Era of Lipid-Lowering Drugs.

Authors:  Philip J Barter; Kerry-Anne Rye
Journal:  Pharmacol Rev       Date:  2016-04       Impact factor: 25.468

5.  Modulation of lipid metabolism with the overexpression of NPC1L1 in mouse liver.

Authors:  Makoto Kurano; Masumi Hara; Koichi Tsuneyama; Koji Okamoto; Naoyuki Iso-O; Teruhiko Matsushima; Kazuhiko Koike; Kazuhisa Tsukamoto
Journal:  J Lipid Res       Date:  2012-08-13       Impact factor: 5.922

6.  Cholesteryl ester transfer protein expression partially attenuates the adverse effects of SR-BI receptor deficiency on cholesterol metabolism and atherosclerosis.

Authors:  Majda El Bouhassani; Sophie Gilibert; Martine Moreau; Flora Saint-Charles; Morgan Tréguier; Francesco Poti; M John Chapman; Wilfried Le Goff; Philippe Lesnik; Thierry Huby
Journal:  J Biol Chem       Date:  2011-03-20       Impact factor: 5.157

7.  Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease.

Authors:  Paolo Zanoni; Sumeet A Khetarpal; Daniel B Larach; William F Hancock-Cerutti; John S Millar; Marina Cuchel; Stephanie DerOhannessian; Anatol Kontush; Praveen Surendran; Danish Saleheen; Stella Trompet; J Wouter Jukema; Anton De Craen; Panos Deloukas; Naveed Sattar; Ian Ford; Chris Packard; Abdullah al Shafi Majumder; Dewan S Alam; Emanuele Di Angelantonio; Goncalo Abecasis; Rajiv Chowdhury; Jeanette Erdmann; Børge G Nordestgaard; Sune F Nielsen; Anne Tybjærg-Hansen; Ruth Frikke Schmidt; Kari Kuulasmaa; Dajiang J Liu; Markus Perola; Stefan Blankenberg; Veikko Salomaa; Satu Männistö; Philippe Amouyel; Dominique Arveiler; Jean Ferrieres; Martina Müller-Nurasyid; Marco Ferrario; Frank Kee; Cristen J Willer; Nilesh Samani; Heribert Schunkert; Adam S Butterworth; Joanna M M Howson; Gina M Peloso; Nathan O Stitziel; John Danesh; Sekar Kathiresan; Daniel J Rader
Journal:  Science       Date:  2016-03-11       Impact factor: 47.728

8.  Negatively cooperative binding of high-density lipoprotein to the HDL receptor SR-BI.

Authors:  Thomas J F Nieland; Shangzhe Xu; Marsha Penman; Monty Krieger
Journal:  Biochemistry       Date:  2011-02-25       Impact factor: 3.162

Review 9.  Scavenger receptor BI: a multi-purpose player in cholesterol and steroid metabolism.

Authors:  Menno Hoekstra; Theo-Jc Van Berkel; Miranda Van Eck
Journal:  World J Gastroenterol       Date:  2010-12-21       Impact factor: 5.742

10.  Inhibition of the central melanocortin system decreases brown adipose tissue activity.

Authors:  Sander Kooijman; Mariëtte R Boon; Edwin T Parlevliet; Janine J Geerling; Vera van de Pol; Johannes A Romijn; Louis M Havekes; Illiana Meurs; Patrick C N Rensen
Journal:  J Lipid Res       Date:  2014-07-12       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.